Abstract:Objective As an idiopathic hypertensive disorder of pregnancy, pre-eclampsia (PE) remains a major cause of maternal and neonatal morbidity and mortality, with no effective strategy for causal treatment. Methods This study was performed by downloading the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) based on the GSE173193 dataset, including single-cell sequencing data from placental samples of two PE patients and two normal controls. Placental cell subpopulations and their transcriptional heterogeneity were compared between PE and healthy pregnancies, and the mechanisms of PE cell dynamics in the hypoxic microenvironment were confirmed by in vitro experiments. Results In this study, we constructed a large-scale single-cell transcriptome ecological landscape of 26,416 cells from healthy pregnant and PE patients placenta and further identified a PE-specific CSNK2B-positive subpopulation of chorionic villous trophoblast (EVT) cells. Specifically, this study revealed that the EVT subpopulation PTBP1 was inactivated by lactonization in the hypoxic microenvironment, resulting in low expression of the N6-methyladenosine (m6A) reading protein IGF2BP2. On the basis of this, low expression of IGF2BP2 inhibits mitochondrial autophagy, causes the accumulation of damaged mitochondria, exacerbates lactic acid accumulation while inducing EVT apoptosis on the one hand. In particular, hypoxia may initially promote oxidative stress through the production of mitochondrial reactive oxygen species. on the other hand, it inhibits EVT adherent spot signaling, decreases EVT invasive ability, leads to impaired placental spiral vessel recast, and promotes PE disease process. In addition, there are interactions between abnormal metabolic signaling of PE-specific EVT subpopulations and microenvironmental immune cells, which activate metabolic inflammation. Conclusion The present study not only provides a new cell biological and genetic basis for elucidating the pathogenesis of PE, but also contributes to the design of an allopathic treatment strategy for PE. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was supported by the Natural Science Foundation of Shandong Province (ZR2021MH223). Nobody at any time received any payment or services from a third party for any aspect of the submitted work. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Ethics Committee of The Affiliated Yantai Yuhuangding Hospital of Qingdao University and written consent was obtained from all patients or their legal guardians participating in the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The datasets analyzed during the current study are available in the GEO database <https://www.ncbi.nlm.nih.gov/geo/>

Gut Dysbiosis Promotes Preeclampsia by Regulating Macrophages and Trophoblasts

Landscapes of gut bacterial and fecal metabolic signatures and their relationship in severe preeclampsia

Gut Microbiota Dysbiosis and Increased Plasma LPS and TMAO Levels in Patients with Preeclampsia

Deep metagenomic characterization of gut microbial community and function in preeclampsia

Corrigendum: the Effect of Gut Microbiota Dysbiosis on Patients with Preeclampsia

The Gut Microbiota Dysbiosis in Preeclampsia Contributed to Trophoblast Cell Proliferation, Invasion, and Migration via lncRNA BC030099/NF-κB Pathway

Remodeling of the Gut Microbiota and Structural Shifts in Preeclampsia Patients in South China

Gut microbiota changes in preeclampsia, abnormal placental growth and healthy pregnant women

Early-Onset Preeclampsia is Associated with Gut Microbial Alterations in Antepartum and Postpartum Women

Decrease in Abundance of Bacteria of the Genus Bifidobacterium in Gut Microbiota May Be Related to Pre-Eclampsia Progression in Women from East China.

Scoping Review of Microbiota Dysbiosis and Risk of Preeclampsia

Research progress on the correlation between gut microbiota and preeclampsia: microbiome changes, mechanisms and treatments

Gut Microbiota Dysbiosis in Preeclampsia Patients in the Second and Third Trimesters

An altered gut microbiome in pre-eclampsia: cause or consequence

Deep metagenomic characterization of the gut virome in pregnant women with preeclampsia

The role of short-chain fatty acids produced by gut microbiota in the regulation of pre-eclampsia onset

Hypoxic Microenvironment Promotes PTBP1 Lactonization and IGF2BP2 Read Defects Mediate the Development of Preeclampsia

Progress in correlation between gut microbiota and preeclampsia

Gut microbiota-derived trimethylamine N-Oxide: a novel target for the treatment of preeclampsia

A Systematic Review of the Molecular Mechanisms

Disturbance of gut microbiota aggravates the inflammatory response and damages the vascular endothelial function in patients with preeclampsia